Sign In
Buy BCDA
$0.97
-0.0006 (-0.0620%)
At Close: Jun 22, 2026
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
08:00am, Thursday, 18'th Jun 2026
SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dise
BioCardia Announces $4.4 Million Financing
08:00am, Monday, 08'th Jun 2026
Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full f
Why Is BioCardia Stock Gaining Friday?
11:06am, Friday, 05'th Jun 2026
BioCardia Inc. (NASDAQ:BCDA) stock is up on Friday as the company is confirming progress toward potential market approval for its CardiAMP cell therapy.
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
08:00am, Friday, 05'th Jun 2026
SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disea
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory a
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
06:20pm, Friday, 15'th May 2026
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
08:00am, Friday, 15'th May 2026
SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
05:10pm, Monday, 11'th May 2026
SUNNYVALE, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
05:10pm, Monday, 11'th May 2026
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
08:00am, Friday, 08'th May 2026
SUNNYVALE, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dis
Tamboran Farmout Pilot Area and BCDA Acreage for Significant Premium in Acreage Value
08:57am, Monday, 30'th Mar 2026
NEW YORK--(BUSINESS WIRE)--Tamboran Resources Corporation (NYSE: TBN, ASX: TBN): Tamboran Resources Corporation Chief Executive Officer, Mr. Todd Abbott, said: “This transaction represents a signifi
BioCardia Q4 Earnings Call Highlights
03:07am, Thursday, 26'th Mar 2026
BioCardia (NASDAQ: BCDA) executives on Tuesday outlined new clinical data for the company's lead cell therapy program and discussed upcoming regulatory interactions in the U.S. and Japan, while also r
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
08:44pm, Tuesday, 24'th Mar 2026
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
BioCardia Reports 2025 Business Highlights and Financial Results
04:05pm, Tuesday, 24'th Mar 2026
SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disea
